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CYTOCHROME P450s AND USES THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims bene?t of US. provisional appli 
cation Ser. Nos. 60/274,421 and 60/275,597, ?led on Mar. 9, 
2001 and Mar. 13, 2001, respectively, both of Which are 
hereby incorporated by reference. 
FIELD OF THE INVENTION 
This invention relates to cytochrome P450s and uses 
thereof. 
BACKGROUND OF THE INVENTION 
Cytochrome P450s encompass a superfamily of oxidases 
responsible for the oxidation of numerous endobiotics and 
thousands of xenobiotics. In addition, in plants, cytochrome 
P450s play important roles in Wound healing, pest resistance, 
signaling, and anti-microbial and anti-fungal activity. 
Capsidiol is a bicyclic, dihydroxylated sesquiterpene pro 
duced by many Solanaceous species in response to a variety 
of environmental stimuli, including exposure to UV (Back et 
al., Plant Cell. Physiol. 389:899-904, 1998) and infection by 
microorganisms (Molot et al., Physiol. Plant Pathol. 379-389, 
1981; Stolle et al., Phytopathology 78:1193-1197, 1988; 
Keller et al., Planta. 205:467-476, 1998). It is the primary 
antibiotic or phytoalexin produced in tobacco in response to 
fungal elicitation, and it is derived from the isoprenoid path 
Way via its hydrocarbon precursor, 5-epi-aristolochene (FIG. 
1). Several of the biosynthetic enZymes leading up to 5-epi 
aristolochene formation have been studied (Chappell, Annu. 
Rev. Plant Physiol. Plant Mol. Biol. 46:521-547, 1995), espe 
cially 5-epi-aristolochene synthase (EAS) (Vogeli and Chap 
pell, Plant Physiol. 88:1291-1296, 1988; Back and Chappell, 
Proc. Natl. Acad. Sci. USA. 93:6841-6845, 1996; Mathis et 
al., Biochemistry 36:8340-8348, 1997; Starks et al., Science 
277:1815-1820, 1997). EAS commits carbon to sesquiter 
pene metabolism by catalyZing the cycliZation of famesyl 
diphosphate (FPP) to 5-epi-aristolochene. HoWever, until the 
present invention, the enZyme(s) responsible for the conver 
sion of 5-epi-aristolochene to capsidiol has yet to be fully 
identi?ed and characterized. 
Biochemical evidence from previous studies in tobacco 
(Whitehead et al., Phytochemistry 28:775-779, 1989) and 
green pepper (Hoshino et al., Phytochemistry 38:609-613, 
1995) have suggested that the oxidation of 5-epi-aris 
tolochene to capsidiol occurs in a tWo step, process With one 
of the hydroxylation steps being constitutive and the other 
being mediated by an elicitor-inducible cytochrome P450 
(FIG. 1). Because 1-deoxycapsidiol had been isolated from 
natural sources (Watson et al., Biochem. Soc. Trans. 11:589, 
1983), Whitehead et al. (Phytochemistry 28:775-779, 1989), 
surmised that perhaps the biosynthesis of this intermediate 
Was due to pathogen induction of a corresponding hydroxy 
lase. They therefore prepared synthetic 1-deoxycapsidiol and 
reported a modest conversion of this compound to capsidiol 
When fed to control or unelicited tobacco cell cultures. This 
Was further supported by their observation that radiolabeled 
5-epi-aristolochene Was only converted to capsidiol When fed 
to elicitor-induced cell cultures but not control cultures. 
Whitehead et al. (Phytochemistry 28:775-779, 1989) there 
fore concluded that the 3-hydroxylase, responsible for 
hydroxylation of 5-epi-aristolochene at C3 to generate 
1-deoxycapsidiol, Was pathogen/elicitor inducible, While the 
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2 
1-hydroxylase, responsible for hydroxylating 1-deoxycap 
sidiol at the C1 to generate capsidiol, Was constitutive. 
Hoshino et al. (Phytochemistry 38:609-613, 1995) added to 
the observations of Whitehead et al. (Phytochemistry 28:775 
779, 1989) by directly measuring 3-hydroxylase-activity in 
microsomal preparations of arachidonic acid-elicited Capsi 
cum annuum fruits and seedlings. These assays consisted of 
incubating 5-epi-aristolochene With microsome preparations 
and subsequently determining the amount of 1-deoxycapsid 
iol generated by a combination of thin-layer chromatography 
(TLC) separations and gas chromatography (GC). Their evi 
dence demonstrated that the conversion of 5-epi-aris 
tolochene to 1-deoxycapsidiol Was dependent on both 
NADPH and O2, and that 1-deoxycapsidiol accumulation in 
vitro Was arrested by the P450 antagonists carbon monoxide 
(Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964), 
ancymidol (Coolbaugh et al., Plant Physiol. 62:571-576, 
1978), and ketoconaZole (Rademacher, Annu. Rev. Plant 
Physiol. Plant Mol. Biol. 51:501-531, 2000). 
Recent results suggest that the hydroxylation of 5-epi 
aristolochene is an important regulated step in capsidiol bio 
synthesis. In studies to evaluate the effectiveness of methyl 
jasmonate as an inducer of capsidiol biosynthesis in tobacco 
cell cultures, Mandujano-ChaveZ et al. (Arch. Biochem. Bio 
phys. 381 :285-294, 2000), reported that the modest accumu 
lation of this phytoalexin Was accompanied by a strong induc 
tion of EAS. This result implied that steps before or after the 
sesquiterpene cyclase reaction Were limiting. Using an in vivo 
assay measuring the conversion rate of radiolabeled 5-epi 
aristolochene to capsidiol, a very limited induction of the 
hydroxylase activities Was observed in cells treated With 
methyl jasmonate relative to that in fungal elicitor-treated 
cells. This result pointed to the hydroxylase reactions as a 
potentially limiting step in capsidiol biosynthesis. 
SUMMARY OF THE INVENTION 
In one aspect, the invention features several isolated cyto 
chrome P450 polypeptides (such as CYP71D20, CYP71D21, 
CYP73A27, CYP73A28, and CYP92A5, and P450s having 
substantial identity to these polypeptides), as Well as isolated 
nucleic acid molecules that encode these P450s. 
In related aspects, the invention features a vector (such as 
an expression vector) including an isolated nucleic acid mol 
ecule of the invention and a cell (for example, a prokaryotic 
cell, such as Agrobacterium or E. coli, or a eukaryotic cell, 
such as a mammalian, insect, yeast, or plant cell) including 
the isolated nucleic acid molecule or vector. 
In yet another aspect, the invention features a transgenic 
plant or transgenic plant component including a nucleic acid 
molecule of the invention, Wherein the nucleic acid molecule 
is expressed in the transgenic plant or the transgenic plant 
component. Preferably, the transgenic plant or transgenic 
plant component is an angiosperm (for example, a monocot or 
dicot). In preferred embodiments, the transgenic plant or 
transgenic plant component is a solanaceous, maiZe, rice, or 
cruciferous plant or a component thereof. The invention fur 
ther includes a seed produced by the transgenic plant or 
transgenic plant component, or progeny thereof. 
In another aspect, the invention features a method of pro 
viding an increased level of resistance against a disease 
caused by a plant pathogen in a transgenic plant. The method 
involves: (a) producing a transgenic plant cell including the 
nucleic acid molecule of the invention integrated into the 
genome of the transgenic plant cell and positioned for expres 
sion in the plant cell; and (b) groWing a transgenic plant from 
the plant cell Wherein the nucleic acid molecule is expressed 
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in the transgenic plant and the transgenic plant is thereby 
provided With an increased level of resistance against a dis 
ease caused by a plant pathogen. 
In another aspect, the invention features a method for pro 
ducing an altered compound, the method including the steps 
of contacting the compound With one or more of the isolated 
polypeptides disclosed herein under conditions alloWing for 
the hydroxylation, oxidation, demethylation, or methylation 
of the compound and recovering the altered compound. 
In still another aspect, the invention features a hydroxylat 
ing agent including any of the isolated polypeptides disclosed 
herein. 
In yet another embodiment, the invention features an iso 
lated nucleic acid molecule that speci?cally hybridizes under 
highly stringent conditions to the complement of any one of 
the sequences described in SEQ ID N012 (CYP71D20), SEQ 
ID N014 (CYP71D21), SEQ ID N016 (CYP73A27), SEQ ID 
N018 (CYP73A28), or SEQ ID N0112 (CYP92A5), Wherein 
such a nucleic acid molecule encodes a cytochrome P450 
polypeptide. 
In another aspect, the invention features a host cell express 
ing a recombinant isoprenoid synthase and a recombinant 
cytochrome P450. In preferred embodiments, the host cell 
further expresses, independently or in combination, a recom 
binant acetyltransferase, methyltransferase, or fatty acyl 
transferase. In other preferred embodiments, the host 
expresses an endogenous or recombinant cytochrome reduc 
tase. Preferably, the host cell is a yeast cell, a bacterial cell, an 
insect cell, or a plant cell. 
In a related aspect, the invention features a method for 
producing an isoprenoid compound, the method including the 
steps of: (a) culturing a cell that expresses a recombinant 
isoprenoid synthase and a recombinant cytochrome P450 
under conditions Wherein the isoprenoid synthase and the 
cytochrome P450 are expressed and catalyze the formation of 
an isoprenoid compound not normally produced by the cell; 
and (b) recovering the isoprenoid compound. In preferred 
embodiments, the host cell further expresses a recombinant 
acetyltransferase, a recombinant methyltransferase, or a 
recombinant fatty acyltransferase. In other preferred embodi 
ments, the host cell expresses an endogenous or recombinant 
cytochrome reductase. Preferably, the host cell is a yeast cell, 
a bacterial cell, an insect cell, or a plant cell. 
In yet another aspect, the invention features an isoprenoid 
compound produced according to the above-mentioned 
methods. 
By “P450 polypeptide,” “cytochrome P450, ” or “P450” is 
meant a polypeptide that contains a heme-binding domain 
and shoWs a C0 absorption spectra peak at 450 nm according 
to standard methods, for example, those described herein. 
Such P450s may also include, Without limitation, hydroxy 
lase activity, dual hydroxylase activity, demethylase activity, 
or oxidase activity. Such enzymatic activities are determined 
using methods Well knoWn in the art. 
By “polypeptide” is meant any chain of amino acids, 
regardless of length or post-translational modi?cation (for 
example, glycosylation or phosphorylation). 
By “substantially identical” is meant a polypeptide or 
nucleic acid exhibiting at least 80 or 85%, preferably 90%, 
more preferably 95%, and most preferably 97%, or even 98% 
identity to a reference amino acid sequence (for example, the 
amino acid sequence shoWn in SEQ ID NOS11, 3, 5, 7, and 1 1) 
or nucleic acid sequence (for example, the nucleic acid 
sequences shoWn in SEQ ID NOS12, 4, 6, 8, and 12, respec 
tively). For polypeptides, the length of comparison sequences 
Will generally be at least 16 amino acids, preferably at least 20 
amino acids, more preferably at least 25 amino acids, and 
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most preferably 35 amino acids. For nucleic acids, the length 
of comparison sequences Will generally be at least 50 nucle 
otides, preferably at least 60 nucleotides, more preferably at 
least 75 nucleotides, and most preferably 110 nucleotides. 
Sequence identity is typically measured using sequence 
analysis softWare (for example, Sequence Analysis Software 
Package of the Genetics Computer Group, University of Wis 
consin Biotechnology Center, 1710 University Avenue, 
Madison, Wis. 53705, BLAST, or PILEUP/PRETTYBOX 
programs). Such software matches identical or similar 
sequences by assigning degrees of homology to various sub 
stitutions, deletions, and/or other modi?cations. Conserva 
tive substitutions typically include substitutions Within the 
following groups: glycine alanine; valine, isoleucine, leu 
cine; aspartic acid, glutamic acid, asparagine, glutamine; 
serine, threonine; lysine, arginine; and phenylalanine, 
tyrosine. 
By an “isolated polypeptide” is meant a P450 polypeptide 
(for example, a CYP71D20 (SEQ ID N01 1), CYP71D21 
(SEQ ID N013), CYP73A27 (SEQ ID N015), CYP73A28 
(SEQ ID N017), or CYP92A5 (SEQ ID N011 1) polypeptide) 
that has been separated from components that naturally 
accompany it. Typically, the polypeptide is isolated When it is 
at least 60%, by Weight, free from the proteins and naturally 
occurring organic molecules With Which it is naturally asso 
ciated. Preferably, the preparation is at least 75%, more pref 
erably at least 90%, and most preferably at least 99%, by 
Weight, a P450 polypeptide. An isolated P450 polypeptide 
may be obtained, for example, by extraction from a natural 
source (for example, a plant cell); by expression of a recom 
binant nucleic acid encoding a P450 polypeptide; or by 
chemically synthesizing the protein. Purity can be measured 
by any appropriate method, for example, column chromatog 
raphy, polyacrylamide gel electrophoresis, or by HPLC 
analysis. 
By “derived from” or “obtained from” is meant isolated 
from or having the sequence of a naturally-occurring 
sequence (e.g., cDNA, genomic DNA, synthetic, or combi 
nation thereof). 
By “isolated nucleic acid molecule” is meant a nucleic acid 
molecule, e.g., a DNA molecule, that is free of the nucleic 
acid sequence(s) Which, in the naturally-occurring genome of 
the organism from Which the nucleic acid molecule of the 
invention is derived, ?ank the nucleic acid molecule. The 
term therefore includes, for example, a recombinant DNA 
that is incorporated into a vector; into an autonomously rep 
licating plasmid or virus; or into the genomic DNA of a 
prokaryote or eukaryote; or that exists as a separate molecule 
(for example, a cDNA or a genomic or cDNA fragment pro 
duced by PCR or restriction endonuclease digestion) inde 
pendent of other sequences. The term “isolated nucleic acid 
molecule” also includes a recombinant DNA Which is part of 
a hybrid gene encoding additional polypeptide sequence. 
By “speci?cally hybridizes” is meant that a nucleic acid 
sequence is capable of hybridizing to a DNA sequence at least 
under loW stringency conditions, and preferably under high 
stringency conditions. For example, high stringency condi 
tions may include hybridization at approximately 420 C. in 
about 50% forrnamide, 0.1 mg/ml sheared salmon sperm 
DNA, 1% SDS, 2><SSC, 10% Dextran sulfate, a ?rst Wash at 
approximately 650 C. in about 2><SSC, 1% SDS, folloWed by 
a second Wash at approximately 650 C. in about 0.1><SSC. 
Alternatively high stringency conditions may include hybrid 
ization at approximately 420 C. in about 50% forrnamide, 0.1 
mg/ml sheared salmon sperm DNA, 0.5% SDS, 5>< SSPE, 1>< 
Denhardt’s, folloWed by tWo Washes at room temperature in 
2><SSC, 0.1% SDS, and tWo Washes at between 55-600 C. in 
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0.2><SSC, 0.1% SDS. Reducing the stringency of the hybrid 
iZation conditions may involve lowering the Wash tempera 
ture and/or Washing at a higher concentration of salt. For 
example, loW stringency conditions may include Washing in 
2><SSC, 0.1% SDS at 400 C. 
By “transformed cell” is meant a cell into Which (or into an 
ancestor of Which) has been introduced, by means of recom 
binant DNA techniques, a DNA molecule encoding (as used 
herein) a P450 polypeptide. 
By “positioned for expression” is meant that the DNA 
molecule is positioned adjacent to a DNA sequence Which 
directs transcription and translation of the sequence (i.e., 
facilitates the production of, for example, a P450 polypeptide, 
a recombinant protein, or an RNA molecule). 
By “reporter gene” is meant a gene Whose expression may 
be assayed; such genes include, Without limitation, beta-glu 
curonidase (GUS), luciferase, chloramphenicol transacety 
lase (CAT), green ?uorescent protein (GFP), beta-galactosi 
dase, herbicide resistant genes, and antibiotic resistance 
genes. 
By “expression control region” is meant any minimal 
sequence suf?cient to direct transcription. Included in the 
invention are promoter elements that are suf?cient to render 
promoter-dependent gene expression controllable for cell-, 
tissue-, or organ-speci?c gene expression, or elements that 
are inducible by external signals or agents (for example, 
light-, pathogen-, Wound-, stress-, or hormone-inducible ele 
ments or chemical inducers such as salicylic acid (SA) or 
2,2-dichloro isonicotinic acid (INA)); such elements may be 
located in the 5' or 3' regions of the native gene or engineered 
into a transgene construct. 
By “operably linked” is meant that a gene and a regulatory 
sequence(s) are connected in such a Way as to permit gene 
expression When the appropriate molecules (for example, 
transcriptional activator proteins) are bound to the regulatory 
sequence(s). 
By “plant cell” is meant any self-propagating cell bounded 
by a semi-permeable membrane and typically is one contain 
ing a plastid. Such a cell also requires a cell Wall if further 
propagation is desired. Plant cell, as used herein includes, 
Without limitation, algae, cyanobacteria, seeds, suspension 
cultures, embryos, meristematic regions, callus tissue, leaves, 
roots, shoots, gametophytes, sporophytes, pollen, and 
microspores. 
By “plant component” is meant a part, segment, or organ 
obtained from an intact plant or plant cell. Exemplary plant 
components include, Without limitation, somatic embryos, 
leaves, stems, roots, ?oWers, tendrils, fruits, scions, and root 
stocks. 
By “transgene” is meant any piece of DNA Which is 
inserted by arti?ce into a cell and typically becomes part of 
the genome, for example, the nuclear or plastidic genome, of 
the organism Which develops from that cell. Such a transgene 
may include a gene Which is partly or entirely heterologous 
(i.e., foreign) to the transgenic organism, or may represent a 
gene homologous to an endogenous gene of the organism. 
By “transgenic” is meant any cell Which includes a DNA 
sequence Which is inserted by arti?ce into a cell and becomes 
part of the genome of the organism Which develops from that 
cell. As used herein, the transgenic organisms are generally 
transgenic plants and the DNA (transgene) is inserted by 
arti?ce into the nuclear or plastidic genome. A transgenic 
plant according to the invention may contain one or more 
engineered traits. 
By “pathogen” is meant an organism Whose infection of 
viable plant tissue elicits a disease response in the plant tissue. 
Such pathogens include, Without limitation, bacteria, myco 
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plasmas, fungi, insects, nematodes, viruses, and viroids. Plant 
diseases caused by these pathogens are described in Chapters 
11-16 of Agrios, Plant Pathology, 3rd ed., Academic Press, 
Inc., NeW York, 1988. 
By “increased level of resistance” is meant a greater level 
of resistance to a disease-causing pathogen in a transgenic 
plant (or cell or seed thereof) of the invention than the level of 
resistance relative to a control plant (for example, a non 
transgenic plant). In preferred embodiments, the level of 
resistance in a transgenic plant of the invention is at least 20% 
(and preferably 30% or 40%) greater than the resistance of a 
control plant. In other preferred embodiments, the level of 
resistance to a disease-causing pathogen is 50% greater, 60% 
greater, and more preferably even 75% or 90% greater than a 
control plant; With up to 100% above the level of resistance as 
compared to a control plant being mo st preferred. The level of 
resistance is measured using conventional methods. For 
example, the level of resistance to a pathogen may be deter 
mined by comparing physical features and characteristics (for 
example, plant height and Weight, or by comparing disease 
symptoms, for example, delayed lesion development, 
reduced lesion siZe, leaf Wilting and curling, Water-soaked 
spots, and discoloration of cells) of transgenic plants. 
By “puri?ed antibody” is meant antibody Which is at least 
60%, by Weight, free from proteins and naturally-occurring 
organic molecules With Which it is naturally associated. Pref 
erably, the preparation is at least 75%, more preferably 90%, 
and most preferably at least 99%, by Weight, antibody, for 
example, an acquired resistance polypeptide-speci?c anti 
body. A puri?ed P450 antibody may be obtained, for 
example, by a?inity chromatography using a recombinantly 
produced P450 polypeptide and standard techniques. 
By “speci?cally binds” is meant an antibody Which recog 
niZes and binds a P450 protein but Which does not substan 
tially recogniZe and bind other molecules in a sample, for 
example, a biological sample, Which naturally includes a 
P450 protein such as CYP71D20, CYP71D21, CYP73A27, 
CYP73A28, or CYP92A5. 
Other features and advantages of the invention Will be 
apparent from the folloWing description of the preferred 
embodiments thereof, and from the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic diagram of a proposed alternative 
pathWay for the biosynthesis of capsidiol in elicitor-treated 
Nicoliana Zabacum cells. 5-epi-aristolochene is synthesiZed 
from FPP by the action of a sequiterpene cyclase, 5-epi 
aristolochene synthase (EAS), and is subsequently hydroxy 
lated at C1 and C3 to form capsidiol. 
FIG. 2 is a graph shoWing an induction time course for 
sesquiterpene cyclase enZyme activity and sesquiterpene 
hydroxylase activity in cellulase-treated cell cultures. Ses 
quiterpene cyclase (5-epi-aristolochene synthase, EAS) 
enZyme activity Was determined in extracts prepared from 
control (open squares) and elicitor-treated (closed squares) 
cells collected at the indicated time points. Sesquiterpene 
hydroxylase activity Was determined using an indirect assay 
for control (open circles) and elicitor-treated (closed circles) 
cells. Cell cultures Were incubated With [3H]-5-epi-aris 
tolochene for 3 hours ending at the indicated time points 
before quantifying the incorporation of radioactivity into 
extracellular capsidiol, a dihydroxylated form of aris 
tolochene (Mandujano-ChaveZ et al., Arch. Biochem. Bio 
phys. 381:285-294, 2000). 
FIG. 3 is a series of graphs shoWing the dose dependent 
inhibition of 5-epi-aristolochene hydroxylase activity by 
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ancymidol and ketoconaZole. Cell cultures Were incubated in 
the presence of cellulase (0.5 ug/mL) plus the indicated con 
centrations of ancymidol (A) or ketoconaZole (B) for 12 hours 
prior to measuring the in vivo 5-epi-aristolochene hydroxy 
lase activity in the cell suspension cultures (squares), or the 
EAS enzyme activity in extracts prepared from the collected 
cells (triangles). The in vitro activity of a puri?ed EAS prepa 
ration (Back and Chappell, J. Biol. Chem. 270:7375-7381, 
1995) Was also measured at the indicated inhibitor concen 
trations as an additional test for non-speci?c effects of these 
inhibitors (circles). 
FIG. 4A is a schematic diagram of the primary structure of 
a generaliZed cytochrome P450 With conserved domains used 
for the design of PCR primers highlighted (SEQ ID NOS:26 
29). 
FIG. 4B is a list of the degenerate P450-speci?c primers 
(SEQ ID NOSz30-36) that Were used in various combinations 
With vector speci?c primers in the ampli?cation of cyto 
chrome P450 cDNA fragments. 
FIG. 4C is a scanned image of an ethidium bromide-stained 
agarose gel shoWing the PCR. products ampli?ed from a 
directional cDNA library prepared With mRNA isolated from 
elicitor-treated cells using the degenerate primer GRRXCP 
(A/G)-for (SEQ ID NO:35) and the T7 vector-speci?c primer 
(SEQ ID NO:37). The T3 vector-speci?c primer is also shoWn 
(SEQ ID NO:38). 
FIG. 5 is a series of Northern blots shoWing the induction 
time course for CYP71D, CYP73A, CYP82E, CYP92A, and 
EAS transcript accumulation in elicitor treated cells. Total 
RNA Was extracted from tobacco suspension cells incubated 
With the cellulase elicitor for the indicated durations, siZe 
fractionated by agarose gel electrophoresis under denaturing 
conditions, and transferred to a nylon membrane before prob 
ing With the respective full-length cDNAs. The uniformity of 
sample loading Was veri?ed by ethidium bromide staining of 
ribosomal RNA (Loading control). 
FIG. 6 is a series of graphs shoWing carbon monoxide (CO) 
difference spectra of the microsomal fraction isolated from 
yeast expressing the CYP92A5 (A) and CYP71D20 (B) 
cDNAs. Expression of the respective plasmid constructs 
engineered into the yeast (WAT11) cells Was induced by a 
galactose treatment, folloWed by isolation of microsomal 
preparations. The difference adsorption spectra of 
microsomes incubated in the presence (solid lines) and 
absence (broken lines) of carbon monoxide Was determined. 
FIG. 7 is a series of gas chromatograms of the reaction 
products formed upon incubation of microsomes isolated 
from WAT11 yeast cells containing the CYP71D20 expres 
sion construct (A and C) or vector control DNA (B and D) 
With sesquiterpene substrates. Microsomes isolated from the 
indicated yeast lines Were incubated With 5-epi-aristolochene 
(A and B) or 1-deoxycapsidiol (C and D) in the presence 
(solid lines) or absence (dashed lines) of NADPH. The iden 
tities of 5-epi-aristolochene, 1-deoxycapsidiol, and capsidiol 
Were veri?ed by mass spectrometry. 
FIG. 8 is a sequence comparison of the amino acid 
sequence of Nicoliana Zabacum 5-epi-aristolochene (sesquit 
erpene) hydroxylase NtCYP71D20 (SEQ ID NO: 1) With 
other plant terpene hydroxylases (SEQ ID NOSz39-43). 
NrCYP71A5v1 (GenBank accession number CAA70575) 
catalyZes the mono-hydroxylation of nerol and geraniol, lin 
ear monoterpenes, While PaCYP71A1 (A35867) catalyZes 
the epoxidation of these substrates (Hallahan et al., Biochim. 
Biophys. Acta. 1201 194-100, 1994). MsCYP71D18 
(AAD44150) and MpCYP7 1 D13 (AAD44151) catalyze the 
mono-hydroxylation at C6 and C3 of limonene, a cyclic 
monoterpene, respectively (Lupien et al., Arch. Biochem. 
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Biophys. 368:181-192, 1999). AtCYP701A3 (AAC39505) 
encodes for kaurene oxidase, Which catalyZes a 3-step reac 
tion including a hydroxylation folloWed by oxidation of a 
diterpene (HelliWell et al., Plant Physiol. 119:507-510, 
1999). ShoWn are sequences from Menlha piperila 
(MpCYP71D13; SEQ ID NO139), Menlha spicala 
(MsCYP71D18; SEQ ID NO:40), Nepela racemosa 
(NrCYP71A5vb 1; SEQ ID NO:41), Nicoliana Zabacum 
(NtCYP71D20; SEQ ID NO:1), Persea americana 
(PaCYP71A1; SEQ ID NO:42), and Arabidopsis Zhaliana 
(CYP701A3; SEQ ID NO:43). Conserved residues are 
shaded. 
DETAILED DESCRIPTION 
Capsidiol is a bicyclic, dihydroxylated sesquiterpene pro 
duced by several Solanaceous species in response to a variety 
of environmental stimuli. It is the primary antimicrobial com 
pound produced by Nicoliana Zabacum in response to fungal 
elicitation, and it is formed via the isoprenoid pathWay from 
5-epi-aristolochene. Much of the biosynthetic pathWay for 
the formation of this compound has been elucidated, except 
for the enZyme(s) responsible for the conversion of the allylic 
sesquiterpene 5-epi-aristolochene to its dihydroxylated form, 
capsidiol. 
Accordingly, an in vivo assay for 5-epi-aristolochene 
hydroxylase-activity Was developed and used to demonstrate 
a dose dependent inhibition of activity by ancymidol and 
ketoconaZole, tWo Well-characterized inhibitors of cyto 
chrome P450 enZymes. Using degenerate oligonucleotide 
primers designed to the Well-conserved domains found 
Within most P450 enZymes, including the heme binding 
domain, cDNA fragments representing four distinct P450 
families (CYP71, CYP73, CYP82, and CYP92) Were ampli 
?ed from a cDNA library prepared against mRNA from elici 
tor-treated cells using PCR. The PCR fragments Were subse 
quently used to isolate full-length cDNAs (CYP71D20 (SEQ 
ID NO: 2) and D21 (SEQ ID NO: 4), CYP73A27 (SEQ ID 
NO: 6) and A28 (SEQ ID NO: 8), CYP82E1 (SEQ ID NO: 
10), and CYP92A5 (SEQ ID NO: 12)), and these in turn Were 
used to demonstrate that the corresponding mRNAs Were all 
induced in elicitor-treated cells, albeit With different induc 
tion patterns. 
There noW folloWs a description of the cloning of several 
P450s from Nicoliana Zabacum. These examples are provided 
for the purpose of illustrating the invention, and are not to be 
considered as limiting. 
Inhibition of the 5-epi-aristolochene to Capsidiol Conversion 
by P450 Antagonists 
Using an indirect assay, a detailed induction time course of 
5EAH activity in elicitor-induced cell cultures Was deter 
mined relative to that of EAS activity (FIG. 2), the Well 
characteriZed sesquiterpene cyclase activity that catalyZes the 
formation of 5-epi-aristolochene from FPP (FIG. 1). Using 
assays for EAS and 5EAH, EAS activity is not detectable in 
control cell cultures, but is induced signi?cantly Within 3 
hours and reaches its maximal level Within 15 to 18 hours of 
elicitor-treatment. Similar to the EAS enZyme activity, 5EAH 
activity Was negligible in control cell cultures. Nonetheless, 
after an apparent lag phase of 8 hours, a rapid induction of 
hydroxylase activity Was observed 10 to 15 hours post elicitor 
addition to the cell cultures, reaching a maximum by 18 hours 
folloWed by a rather gradual decline of 10 to 20% over the 
next 8 hours. 
Tobacco cell suspension cultures treated With cellulase 
plus varying concentrations of ancymidol or ketoconaZole 
US 7,405,057 B2 
Were pre-incubated for 12 hours before measuring the cells’ 
ability to convert exogenous supplied [3H] labeled 5-epi 
aristolochene to radiolabeled capsidiol during a subsequent 3 
hour incubation period (FIG. 3). Apparent activity of 5EAH 
Was inhibited in a dose-dependent manner With approxi 
mately 50% inhibition by either 25 uM ancymidol or keto 
conaZole, and more than 80% by 75 uM ancymidol and 95% 
by 100 uM ketoconaZole (FIGS. 3A and B). Importantly, 
neither the in vitro activity of recombinant EAS nor the induc 
tion of EAS in the elicitor-treated cell cultures Was signi? 
cantly affected by ancymidol at concentrations as high as 100 
uM (FIG. 3A). KetoconaZole also does not appear to affect the 
in vitro activity of EAS. HoWever, the inducibility of cyclase 
activity in elicitor-treated cell extracts Was inhibited by keto 
conaZole at concentrations above 50 uM (FIG. 3B). There 
fore, the speci?city of ketoconaZole as an inhibitor of P450 
type reactions should be assessed at or beloW a concentration 
of 50 uM under these experimental conditions. 
Isolation of Elicitor-inducible Cytochrome P450 cDNAs 
A tWo-step approach for the isolation of candidate P450 
cDNAs Was folloWed. A PCR strategy Was ?rst employed 
using a directional cDNA library prepared against mRNA 
isolated from elicitor-induced cells as the template and 
degenerate PCR primers (FIG. 4). Sequence alignments of 
cytochrome P450s from multiple families across kingdoms 
Were used to identify conserved regions to Which a series of 
degenerate primers Were prepared (FIGS. 4A and B). In clon 
ing experiments, 450 to 550 bp products Were expected from 
reactions utilizing the primer prepared to the heme-binding 
domain (GRRXCP(A/G)) (SEQ ID NOS:27 and 28) and the 
T7 vector primer (FIG. 4C). The mixtures of reaction prod 
ucts Were shotgun cloned, and approximately 100 of the 
cloned PCR fragments Were sequenced. About half of the 
sequenced DNAs contained signature sequences typical of 
P450 enZymes as revealed by BlastX database searches, and 
these corresponded to typical plant P450 family members of 
the CYP71, CYP73, CYP92, and CYP82 classes. Each of 
these PCR fragments Was isolated multiple times in separate 
experiments. In addition, We isolated fall-length cDNAs for 
these P450 family members. Table 1 compares the similarity 
and identity of the ?ll-length cDNAs of P450 family members 
With those of their nearest family member in the GenBank 
database. In addition, FIG. 8 shoWs an amino acid alignment 
of several terpene cytochrome P450s. Alignments Were per 
formed using the algorithm of the MACVECTOR softWare 
suite. 
TABLE 1 
Full-length cDNAs cloned from an elicited cDNA library 
Cytochrome P450 Nearest relative/ 
cDNA clone accession number % identity % similarity 
CYP71D20 CYP71D7 (S. chacoense) 76.5 88.8 
Gen EMBL U48435 
CYP71D21 CYP71D7 (S. chacoense) 76.3 88.8 
Gen EMBL U48435 
CYP73A27 CYP73A15 (R vulgaris) 79.4 92.6 
Gen EMBL Y09447 
CYP73A28 CYP73A15 (R vulgaris) 79.2 92.4 
Gen EMBL Y09447 
CYP82E1 CYP82E1 (N. labacum) 100.0 100.0 
Gen EMBL AB015762 
CYP92A5 CYP92A3 (N. labacum) 95.5 98.6 
Gen EMBL X96784 
The cloned fragments Were used in a second step to isolate 
full-length clones from the cDNA library. Screening the 
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cDNA library by hybridiZation With the CYP71 and CYP73 
gene fragments yielded four full-length cDNAs, tWo 
CYP71Ds and tWo CYP73As. The former clones Were des 
ignated CYP71D20 and CYP71D21, and the latter Were des 
ignated CYP73A27 and CYP73A28. The other tWo cDNA 
fragments corresponded to tobacco cDNAs already found in 
the GenBank database, CYP82E1 and CYP92A3. These tWo 
cDNAs Were cloned using speci?c primers designed With the 
help of the available sequence information to amplify the 
full-length cDNA 
Induction of Cytochrome P450 mRNAs in Elicitor-treated 
Cells 
To correlate a biochemical role for P450s in sesquiterpene 
metabolism, RNA blot analyses Were used to determine the 
steady-state levels of the mRNAs coding for all four of the 
cytochrome P450 clones and EAS in control and elicitor 
treated cells (FIG. 5). The mRNAs for all four of the P450s 
Were rapidly and transiently induced With slightly different 
time courses relative to one another and to the EAS mRNA. 
CYP73A27 mRNA, for instance, displayed an induction pat 
tern similar to that of EAS With the maximum mRNA level 
occurring 9 to 12 hours after elicitation. While the EAS 
mRNA remained high throughout the duration of the experi 
ment, the CYP73A27 mRNA Was negligible in cells 24 hours 
after elicitor-treatment. In contrast, the CYP71D mRNA Was 
more rapidly induced than the EAS mRNA, reached its maxi 
mum 6 to 9 hours after elicitation, and Was declining by 12 
hours When the EAS mRNA level Was still very high. 
Functional Identi?cation of CYP71D20 as 5-epi-aris 
tolochene Hydroxylase 
To ascribe functional identity to the various P450 cDNAs, 
full-length cDNAs for CYP7 1 D20, CYP82E1 and CYP92A5 
Were inserted into the yeast expression vector pYeDP60 (Ur 
ban et al., Biochimie 72:463-472, 1990; Pompon et al., Meth 
ods EnZymol. 272:51-64, 1996) and the expression ofeach in 
WAT11, a yeast line containing an integrated Arabidopsis 
Zhaliana cytochrome reductase gene (Pompon et al., Methods 
EnZymol. 272:51-64, 1996; Urban et al., J. Biol, Chem. 272: 
19176-19186, 1997), Was determined. Engineering the 
CYP73A27 cDNA required an extra modi?cation because of 
an unusually long N-terminus With several hydrophilic resi 
dues that may interfere With proper intracellular targeting 
(Nedelkina et al., Plant Mol. Biol. 39:1079-1090, 1999). This 
unusual leader sequence therefore Was replaced With the 
membrane anchoring sequence of CYP73A1, a cinnamate 
4-hydroxylase previously demonstrated to express Well in 
yeast (Fahrendorf and Dixon, Arch. Biochem. Biophys. 305: 
509-515, 1993; Pompon et al., Methods EnZymol. 272:51-64, 
1996). Expression of all these cDNAs Was under the control 
of the glucose-repressible, galactose-inducible GAL10 
CYC1 promoter (Guarente et al., Proc. Natl. Acad. Sci. 
USA. 79:7410-7414, 1982), and expression Was compared 
to yeast transformed With the parent pYeDP60 vector (con 
trol) alone. 
After induction With galactose for approximately 16 hours, 
control cells and cells containing the various P450 constructs 
Were collected, and microsomes prepared from each Were 
analyZed for general P450 expression by CO-difference spec 
troscopy (Omura and Sato, J. Biol. Chem. 239:2370-2378, 
1964). Microsomes prepared from cells containing the 
CYP71D20 (FIG. 6A) and CYP92A5 (FIG. 6B) constructs 
both shoWed characteristic CO difference spectra With peaks 
at 450 nm, indicating that the encoded proteins Were assem 
bling properly With their heme cofactor. Using the extinction 
coel?cient of 91 mM‘1 cm‘1 for heme binding proteins 
(Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964), it 
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Was determined that approximately 107 pmol of CYP71D20 
and 268 pmol of CYP92A5 Were expressed in the yeast cells 
per milligram of total yeast protein. 
Both 5-epi-aristolochene and 1-deoxycapsidiol Were 
metabolized to only one product With the same retention time 
as capsidiol. Obvious by its absence, no reaction product 
having a retention time similar to deoxycapsidiol Was detect 
able in the 5-epi-aristolochene incubations (FIG. 7). Co-in 
jection of authentic capsidiol With the respective reaction 
products resulted in a single GC peak having a 16.2 minute 
retention time, identical to capsidiol. Mass spectra patterns 
for the separate reaction products Were identical to that for the 
capsidiol standard (EIMS m/z 236, 221, 203, 185, 175, 163, 
157, 133, 121, 107, 93, 79, 67, 55, 43, 41). 
The in vivo assay data presented in FIGS. 2 and 3 of the 
current Work indicate that the conversion of 5-epi-aris 
tolochene is catalyzed by at least one inducible cytochrome 
P450 mediated reaction. 
Furthermore, any of the cytochrome p450 polypeptides 
described herein may include one or more hydroxylase activi 
ties Which can incorporate hydroxyl groups into at least tWo 
distant sites on an isoprenoid compound. The addition of 
these hydroxyl groups may occur, for example, sequentially, 
by adding a hydroxyl group ?rst to one site and then the other, 
in either order. Moreover, such hydroxylases may be mutated 
to limit their ability to hydroxylate a substrate at only one site, 
or, alternatively, to provide stereochemical speci?city to their 
hydroxylating activity. 
The above-described experiments Were performed using 
the folloWing materials and methods. 
Chemicals 
Standard laboratory reagents Were purchased from Becton 
Dickinson Microbiology Systems (Sparks, Md.), FisherBio 
tech (Fair LaWn, N1.) and Sigma Chemical Company (St. 
Louis, Mo.). 
Biological Materials and Induction Treatments 
Nicoliana Zabacum cv. KY14 plants and cell suspension 
cultures Were used. Cell suspension cultures Were maintained 
in modi?ed Murashige-Skoog (Vogeli and Chappell, Plant 
Physiol. 88:1291-1296, 1988). Cultures in their rapid phase 
of groWth (3 days old) Were used for all experiments. At the 
indicated times, cells Were collected and separated from 
media by vacuum ?ltration and stored at —80° C. 
Induction treatments Were performed by the addition of the 
fungal elicitors, cellulase (Trichoderma viride, Type RS, 
Onozuka) or paraciticein (O’Donohue et al., Plant Mol. Biol. 
27:577-586, 1995) at the indicated concentrations. Paraciti 
cein Was puri?ed from E. coli cells overexpressing a recom 
binant paraciticein protein containing a carboxy-terminal his 
tidine puri?cation tag. 
In vivo 5-epi-aristolochene Hydroxylase Assay and Inhibi 
tion Studies 
5-epi-aristolochene hydroxylase-activity Was measured as 
the incorporation of [3H] -5-epi-aristolochene into extracellu 
lar capsidiol by intact cells. [3H]-5-epi-aristolochene Was 
produced by incubating an excess of [1 -3 H] famesyl diphos 
phate (1 pM, 20.5 Ci/mmol) With recombinant 5-epi-aris 
tolochene synthase (Back et al., Arch. Biochem. Biophys. 
315:527-532, 1994; Rising et al., J. Am. Chem. Soc. 122: 
1861 -1 866, 2000). The hexane extractable radioactivity from 
reactions Was treated With a small amount of silica to remove 
any famesol or residual FPP before quantifying the yield of 
radioactive 5-epi-aristolochene by liquid scintillation count 
ing. The hexane solvent Was removed under a gentle stream of 
N2 gas, and the dried residue Was re-dissolved in acetone. 
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Control and elicitor-treated cells Were then incubated With 
[3H]-5-epi-aristolochene (approximately 100,000 dpm at 2.5 
pM) for 3 hour periods at various points during an induction 
time course before collecting the cell and media samples. 
Detection and quanti?cation of capsidiol in the extracellular 
culture media Was performed as reported previously (Chap 
pell et al., Phytochemistry 26:2259-2260, 1987), and the 
amount of radioactivity incorporated into capsidiol Was deter 
mined. For these determinations, samples Were separated by 
TLC, and the zones corresponding to capsidiol Were scraped 
from the plate for scintillation counting. 
Inhibition studies Were performed by the addition of the 
P450 inhibitors ancymidol (Coolbaugh et al., Plant Physiol. 
62:571-576, 1978; Hoshino et al., Phytochemistry 38:609 
613, 1995) and ketoconazole (Hoshino et al., Phytochemistry 
38:609-613, 1995; Rademacher, Annu. Rev. Plant Physiol. 
Plant Mol. Biol. 51:501-531, 2000) directly to the cell cul 
tures or enzyme assay mix. Cell cultures Were incubated in 
the presence of cellulase (0.5 pg/ml) and indicated concen 
trations of ancymidol or ketoconazole for 12 hours prior to the 
addition of [3H]-5-epi-aristolochene. After a further 3 hour 
incubation period, the cells and media Were collected. The 
amount of radioactivity incorporated into extracellular cap 
sidiol Was determined as described above. To evaluate sec 
ondary effects of these inhibitors, the level of inducible ses 
quiterpene cyclase activity in the collected cells Was 
determined according to (Vogeli et al., Plant Physiol. 93: 182 
187, 1990), as Well as in vitro assays With puri?ed recombi 
nant EAS (Back et al., Arch. Biochem. Biophys. 315:527 
532, 1994) incubated With the indicated concentrations of 
ancymidol and ketoconazole. 
All experiments Were replicated in several independent 
trials. While the absolute values presented may have varied 
betWeen experiments by as much as 50%, the trends and time 
courses Were consistent throughout. 
Construction of an Elicitor-induced cDNA Library 
Cell cultures Were incubated With fungal elicitor (0.5 pg 
cellulase/ml) for 6 hours before collecting the cells by ?ltra 
tion. The cells Were kept frozen at —80° C. until total RNA Was 
extracted from them using Trizol (Life Technologies, Rock 
ville, Md.) according to the manufacturer’s instructions. Poly 
(A)+RNA Was puri?ed by tWo rounds of oligo (dT) cellulose 
column chromatography (Life Technologies, Rockville, 
Md.). cDNA synthesis and library construction Were subse 
quently carried out using the UNI-ZAP XR library kit (Strat 
agene, La Jolla, Calif.), according to manufacturer’s instruc 
tions. 
PCR Cloning Strategy 
Cytochrome P450 cDNA fragments Were ampli?ed from 
the elicitor-induced cDNA library using various combina 
tions of degenerate forWard and reverse primers With the 
vector-speci?c T3 and T7 primers. The template DNA Was 
prepared from a 500 pl aliquot of the elicitor-induced cDNA 
library (3><106 pfu/pl) by heat denaturation at 70° C. for 10 
minutes, folloWed by phenol/ chloroform extraction, ethanol 
precipitation and re-suspension in 500 pl of sterile, deionized 
Water. Ampli?cation reactions Were performed in 50 pl vol 
umes containing 50 mM KCl; 10 mM Tris-HCl, pH 8.8; 1.5 
mM MgCl2; 200 pM of each dNTP; 2 pl template DNA; 20 
pmol each of forWard and reverse primer; and 1 unit Taq 
Polymerase (Life Technologies, Rockville, Md.). Reactions 
Were preheated at 94° C. for 2 minutes, folloWed by thirty-?ve 
cycles of denaturing at 94° C. for 1 minute, annealing at 50° 
C. for 1 minute 30 seconds, and polymerization at 72° C. for 
2 minutes. The reactions Were completed by a 10-minute 
extension at 72° C. Aliquots of the reaction products Were 
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examined for DNA products by agarose gel fractionation, and 
ligated directly into the pGEM-T Easy vector (Promega, 
Madison, Wis.). Resulting recombinant plasmids containing 
insert DNAs Within the expected size range Were sequenced 
using T7 and Sp6 primers. 
DNA Sequencing 
All the DNA sequencing reactions Were performed using 
the BIGDYETM Terminator Cycle sequencing kit (Perkin 
Elmer, Wellesley, Mass.) With the sequences being read on an 
automated ABI Prism 310 Genetic Analyzer (Applied Bio 
systems, Foster City, Calif.). Computer assessment of the 
DNA sequence information Was performed using the 
MACVECTOR (Oxford Molecular, Madison, Wis.) softWare 
package. 
cDNA Library Screening 
The cDNA library Was screened With digoxigenin labeled 
probes. A 258 bp DNA fragment ampli?ed from the pGEM 
deg6.4 clone using gene-speci?c forWard (5'-GGCG 
GAGAATTTGTCCTGGAATGTCATTTGGTTTAG-3' 
(SEQ ID NO: 13)) and reverse (5'-GTACAATAGTGAGGT 
TGACAATG-3' (SEQ ID NO: 14)) primers; and a 374 bp 
DNA fragment ampli?ed from the pBKS-CYPB3.843 clone 
With speci?c forWard (5'-GGTGGTTGTGAATGCATG-3' 
(SEQ ID NO: 15)) and reverse (5'-TTATGCAGCAATAG 
GCTTGAAGACA-3' (SEQ ID NO: 16)) primers, Were used 
to screen for CYP71Ds. The probes Were labeled With digoxi 
genin-11-dUTP using the PCR DIG Labeling Mix (Roche 
Molecular Biochemicals, Indianapolis, Ind.), hybridized to 
plaque lifts of the cDNA library plated at approximately 
10,000 PFUs per 150 mm plate, and Was hybridization 
detected With the DIG detection system according to the 
manufacturer’ s instructions (Roche Molecular Biochemicals, 
Indianapolis, Ind.). Plaques exhibiting strong hybridization 
Were plaque puri?ed, auto-subcloned to their plasmid forms 
according to the manufacturer’s recommendations (Strat 
agene, La Jolla, Calif.), and then subjected to DNA sequenc 
ing as described above. 
RNA Analysis 
RNA gel blot analysis Was carried out using 10 pg aliquots 
of total RNA. RNA samples Were heat-denatured at 70° C. for 
15 minutes in sample buffer (1>< MOPS, 50% formamide, 
16% formaldehyde, 30% glycerol, and 3% ethidium bro 
mide), and size fractionated on a 1 .2% agarose gel containing 
1>< MOPS and 18.1% formaldehyde. Uniformity of sample 
loading Was determined by visual inspection of the gel for 
rRNA bands. The RNAs Were then transferred to a Zeta Probe 
nylon membrane (Bio-Rad Laboratories, Hercules, Calif.) 
and hybridized according to the manufacturer’s recommen 
dations. Full-length cDNAs probes Were labeled With [32P] 
dCTP (PRIME-IT Kit, Stratagene, La Jolla, Calif.) prior to 
hybridization. After hybridization, the membranes Were 
Washed in 2><SSC/0.1% SDS once at room temperature fol 
loWed by sequential Washes in 0.2><SSC/0.1% SDS at 42° C. 
and 65° C. Hybridization Was detected With a Phosphoimager 
(Molecular Dynamics, model 445 SI). 
Construction of Yeast Expression Vectors. 
The coding regions of the P450 cDNAs Were cloned into 
the pYeDP60 expression vector (Urban et al., J. Biol. Chem. 
272: 19176-19186, 1990; Pompon et al., Methods Enzymol. 
272:51-64, 1996). Appropriate BamHI, EcoRi, and SstI 
restriction sites (underlined) Were introduced via PCR prim 
ers containing these sequences either upstream of the trans 
lation start site (ATG) or doWnstream of the stop codon (TAA 
or TGA). The primers used to amplify the CYP71D20 cDNA 
Were 5'-GGGGGATCCATGCAATTCTTCAGCTTGGTT 
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TCC-3' (SEQ ID NO: 17) and 5'-GGGGAATTCTTACT 
CTCGAGAAGGTTGATAAGG-3' (SEQ ID NO: 18); for 
the CYP82E1 cDNA 5'-CCCGGATCCATGTATCATCT 
TCTTTCTCCC-3' (SEQ ID NO: 19) and 5'-GGG 
GAATTCTCAATATTGATAAAGCGTAGGAGG-3' (SEQ 
ID NO: 20); and for the CYP92A3 cDNA 5'-CCC 
GGATCCATGCAATCCTTCAGCTTGGTTTCC-3' (SEQ 
ID NO: 21) and 5'-GGGGAGCTCTCACTCGCAAGAA 
GATTGATAAGG-3' (SEQ ID NO: 22). TWo long, over 
lapping (italicized) primers 5'-GCCATTATCGGCGCAA 
TACTAATCTCCAAACTCCGCGGTAAAAAATTCAAG 
CTCCCACCTGGTCCAACAGCAGTC-3' (SEQ ID NO: 
23) and 5'-GGGGGATCCATGGACCTCCTCCTCATAGA 
AAAAACCCTCGTCGCCTTATTCGCCGCCATTATCG 
GCGCAATACTA-3' (SEQ ID NO: 24) coding for the N-ter 
minal sequence of CYP73A1 (GenEMBL Z 17369) up to the 
hinge region Were used for the modi?cation of the membrane 
anchoring segment of CYP73A27 to avoid possible problems 
With intracellular targeting due to the unusual N-terminus 
(Nedelkina et al., 1999); the reverse primer used for both 
ampli?cations Was 5'-GGGGAGCTCTTATGCAGCAAT 
AGGCTTGAAGAC-3' (SEQ ID NO: 25). CYP71D20 and 
CYP73A27 Were ampli?ed using full-length cDNA tem 
plates, Whereas CYP82E1 and CYP92A5 Were ampli?ed 
directly from the cDNA library template. Ampli?cations 
Were performed in 50 pl reactions containing 1>< Pfx ampli 
?cation buffer; 1 mM MgSO4; 300 pM of each dNTP; 10 ng 
template DNA; 20 pmol each of forWard and reverse primer; 
and 1.25 units PLATINUM® Pfx Polymerase (Life Tech 
nologies, Rockville, Md.). Reactions Were preheated at 94° 
C. for 2 minutes, folloWed by thirty-?ve cycles of denaturing 
at 94° C. for 15 seconds, annealing at 55° C. for 30 seconds, 
and elongating at 68° for 1.5 minutes. PCR products Were 
ligated into the pGEM-T EASY vector (Promega, Madison, 
Wis.) and subcloned into the pYeDP60 vector. The resulting 
constructs Were validated by a combination of PCR and DNA 
sequencing. 
Yeast Expression Studies 
Veri?ed pYeDP60-P450 cDNA constructs Were introduced 
into the yeast WAT1 1 line, a derivative of the W3 03-1B strain 
(MAT a; ade 2-1; his 3-11; leu 2-3, -112; ura 3-1; canR; cyr”), 
provided by Dr. P. Urban (Centre de Genetique Moléculaire, 
CNRS, Gif- sur-Yvette, France). The endogenous NADPH 
cytochrome P450 reductase (CPR1) locus has been replaced 
WithATR1, a NADPH-cytochrome P450 reductase fromAra 
bidopsis Zhaliana (Pompon et al., Methods Enzymol. 272:51 
64, 1996; Urban et al., J. Biol. Chem. 272:19176-19186, 
1997), in the WAT1 1 line. Yeast Was groWn overnight in a 30° 
C. shaker in YPAD (1 g/l yeast extract; 1 g/l peptone; 20 g/l 
glucose; 200 mg/l adenine) liquid media. Cultures Were har 
vested at anA600 betWeen 0.5 and 1.5. Cells Were collected by 
centrifugation at 2,500><g for 5 minutes at 4° C., and resus 
pended in ice-cold, sterile dH2O. Cells Were pelleted again as 
above and resuspended in 1 M sorbitol. Forty pl of yeast 
suspension Was mixed With 0.5 to 1 pg plasmid DNA (in <5 pl 
dH2O) in a pre-chilled 0.5 ml tube, and transferred to a chilled 
cuvette With a 0.2 cm electrode gap. One pulse at 1.5 kV, 25 
pF, and 200 Ohms Was applied by an Eppendorf Electropo 
rator (model 2510).A mixture of 500 pl ofYPAD/1 M sorbitol 
Was immediately added to the electroporated cells. Cells Were 
alloWed to recover at 30° C. for 1 hour, then spread onto SGI 
plates (1 g/l bactocasamino acids; 7 g/l yeast nitrogenbase; 20 
g/l glucose; 20 mg/l tryptophan; and 20 g/l agar). Trans 
formed colonies appeared after 3 to 6 days of incubation at 
30° C. Recombinant plasmids Were con?rmed by PCR assays 
performed directly on randomly selected yeast colonies. 
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For expression studies, one colony Was added to SGI media 
(1 g/l bactocasamino acids; 7 g/l yeast nitrogen base; 20 g/l 
glucose; and 20 mg/l tryptophan) and grown at 30° C. for 
approximately 24 hours.An aliquot of this culture Was diluted 
1:50 into 250 ml of YPGE (10 g/l bactopeptone; 10 g/l yeast 
extract; 5 g/l glucose; and 3% ethanol by volume) and the 
cells Were groWn until all glucose Was consumed. The 
absence of glucose Was determined by placing a 200 pl ali 
quot of culture into a 1.5 ml tube, inserting a DIASTIX 
urinalysis reagent strip (Bayer, Elkhart, Ind.) for 30 seconds, 
and observing colorimetric changes indicating glucose levels. 
Induction Was initiated by the addition of 5 grams of galactose 
(?nal concentration of 2%). The cultures Were maintained at 
30° C. for an additional 16 hours before collecting the cells by 
centrifugation at 7,000><g for 10 minutes. The pelleted cells 
Were Washed With 100 ml of TES buffer (50 mM Tris-HCl pH, 
7.5; 1 mM EDTA; 0.6 M sorbitol). The cells Were centrifuged 
as above, resuspended in 100 ml of TES-M (TES supple 
mented With 10 mM 2-mercaptoethanol), and alloWed to 
incubate at room temperature for 10 minutes. The yeast cells 
Were centrifuged again at 7,000><g for 10 minutes, and the 
pellet Was resuspended in 2.5 ml extraction buffer (1% bovine 
serum albumin, fraction V; 2 mM 2-mercaptoethanol; 1 mM 
phenylmethylsulfonyl ?uoride, all dissolved in TBS). Glass 
beads (0.5 mm in diameter, Biospec Products, Inc., Bartles 
ville, Okla.) Were added until skimming the surface of the cell 
suspension. Cell Walls Were disrupted manually by hand 
shaking in a cold room for 10 min at 30 second intervals 
separated by 30 second intervals on ice. Cell extracts Were 
transferred to a 50 ml centrifuge tube, the glass beads Were 
Washed three times With 5 ml of extraction buffer, and the 
Washes Were pooled With the original cell extracts. 
Microsomes Were prepared by differential centrifugation at 
10,000 g for 10 minutes at 4° C. to remove cellular debris, 
folloWed by centrifugation at 100,000><g for 70 minutes at 4° 
C., and microsomal pellets Were resuspended in 1.5 ml 
TEG-M buffer (50 mM Tris-HCl, pH 7.5; 1 mM EDTA; 20% 
glycerol; and 1.5 mM 2-mercaptoethanol) and stored froZen 
at —80° C. until further assayed. 
CO Difference Spectra 
Fe2+.CO vs. Fe2+ difference spectroscopy (Omura and 
Sato, J. Biol. Chem. 239:2370-2373, 1964) Was performed 
using 0.4 ml of microsomes suspended in 1.6 ml of 50 mM 
Tris-HCl, pH 7.5; 1 mM EDTA; and 20% glycero. A small 
amount of the reducing agent, sodium dithionite, Was added, 
and the mixture Was distributed betWeen tWo cuvettes. A 
baseline Was recorded betWeen 400 and 500 nm on a Perkin 
Elmer Lambda 18 UV/visible spectrophotometer. CO Was 
then bubbled into the sample cuvette for 1 minute, and the 
difference spectrum recorded again. The amount of func 
tional P450 Was estimated based on an absorbance coef?cient 
of 91 mM_l.cm_l. 
5-epi-aristolochene-1, 3-hydroxylase Assays 
5-epi-aristolochene-1, 3-hydroxylase assays Were per 
formed in 0.5 ml polyethylene tubes in 100 pl volumes. 5-epi 
aristolochene or 1-deoxycapsidiol dissolved in hexane Was 
added to the tube, and the organic solvent Was removed by 
incubation of the open tube at 30° C. 5-epi-aristolochene and 
1-deoxycapsidiol Were resuspended in 2 pl dimethyl sulfox 
ide before adding the reaction mixture. Reactions Were car 
ried out in 100 mM Tris-HCl, pH 7.5, to Which microsomal 
protein Was added to a ?nal concentration of 1 mg/ml. Reac 
tions Were initiated by the addition of 2 mM NADPH. The 
?nal concentration of 5-epi-aristolochene and 1-deoxycap 
sidiol in these assays varied from 20 to 50 uM. After incuba 
tions for variable lengths of time at 30° C., the reactions Were 
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extracted With tWo volumes of ethyl acetate. The organic 
extracts Were concentrated and evaluated by GC and GC-MS 
along With standards of 5-epi-aristolochene (Whitehead et al., 
Phytochemistry 28:775-779, 1989; Rising et al., J. Am. 
Chem. Soc. 122: 1 861-1866, 2000), 1-deoxycapsidiol 
(Whitehead et al., Phytochemistry 29:479-182, 1990), and 
capsidiol (Whitehead et al., Phytochemistry 26:1367-1369, 
1987; Milat et al., Phytochemistry 30:2171-2173, 1991). GC 
analysis Was routinely performed With an HP5890 GC 
equipped With a HeWlett-Packard HP-5 capillary column (30 
m><0.25 mm, 0.25 um phase thickness) and FID as described 
previously (Rising et al., J. Am. Chem. Soc. 122: 1861-1866, 
2000). GC-MS analysis Was performed at the University of 
Kentucky Mass Spectrometry Facility using a Varian 3400 
gas chromatograph and a Finnigan INCOS 50 quadrupole 
mass selective detector. The GC Was equipped With a J&W 
DB-5 ms capillary column (15 m><0.25 mm, 0.25 pm phase 
thickness) and run With He as the carrier gas (10 psi.). Split 
less injections Were done at an injection port temperature of 
280° C. The column temperature Was maintained at 40° C. for 
1 minute and then increased to 280° C. at 10° C. per minute. 
FolloWing separation by the GC column, samples Were intro 
duced directly into the electron impact ioniZation source. 
Mass spectra Were acquired at 70 eV, scanning from 40-440 
Da in 1 second. 
Production of Cytochrome P450s 
Using the standard molecular techniques described herein, 
the isolation of additional cytochrome P450 coding 
sequences is readily accomplished. For example, using all or 
a portion of the amino acid sequence of any of the disclosed 
P450s, one may readily design P450-speci?c oligonucleotide 
probes, including P450 degenerate oligonucleotide probes 
(i.e., a mixture of all possible coding sequences for a given 
amino acid sequence). These oligonucleotides may be based 
upon the sequence of either DNA strand and any appropriate 
portion of the P450 nucleotide sequence. General methods for 
designing and preparing such probes are provided, for 
example, in Ausubel et al., 2000, Current Protocols in 
Molecular Biology, Wiley Interscience, NeW York, and 
Berger and Kimmel, Guide to Molecular Cloning Tech 
niques, 1987, Academic Press, NeW York. These oligonucle 
otides are useful for P450 gene isolation, either through their 
use as probes capable of hybridiZing to a P450 complemen 
tary sequence, or as primers for various ampli?cation tech 
niques, for example, polymerase chain reaction (PCR) clon 
ing strategies. 
Hybridization techniques and screening procedures are 
Well knoWn to those skilled in the art and are described, for 
example, in Ausubel et al. (supra); Berger and Kimmel (su 
pra); Chen et al., Arch. Biochem. Biophys. 324:255, 1995; 
and Sambrook et al., Molecular Cloning: A Laboratory 
Manual, Cold Spring Harbor Laboratory Press, NeW York. If 
desired, a combination of different oligonucleotide probes 
may be used for the screening of a recombinant DNA library. 
The oligonucleotides may be detectably-labeled using meth 
ods knoWn in the art and used to probe ?lter replicas from a 
recombinant DNA library. Recombinant DNA libraries are 
prepared according to methods Well knoWn in the art, for 
example, as described inAusubel et al. (supra), or they may be 
obtained from commercial sources. 
As discussed above, P450 oligonucleotides may also be 
used as primers in a polymerase chain reaction (PCR) ampli 
?cation cloning strategy. PCR methods are Well knoWn in the 
art and are described, for example, in PCR Technology, 
Erlich, ed., Stockton Press, London, 1989; PCR Protocols: A 
Guide to Methods and Applications, Innis et al., eds., Aca 
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demic Press, Inc., NeWYork, 1990; andAusubel et al. (supra). 
Primers are optionally designed to allow cloning of the ampli 
?ed product into a suitable vector, for example, by including 
appropriate restriction sites at the 5' and 3' ends of the ampli 
?ed fragment (as described herein). If desired, a P450 gene 
may be isolated using the PCR “RACE” technique, or Rapid 
Ampli?cation of cDNA Ends (see, e.g., Innis et al. (supra)). 
By this method, oligonucleotide primers based on a P450 
sequence are oriented in the 3' and 5' directions and are used 
to generate overlapping PCR fragments. These overlapping 
3'- and 5'-end RACE products are combined to produce an 
intact full-length cDNA. This method is described in Innis et 
al. (supra); and Frohman et al., Proc. Natl. Acad. Sci. USA 
8518998, (1988). 
Additional methods for identifying sequences encoding 
P450 s are provided in Maughan et al (Arch. Biochem. Bio 
phys. 3411104-111, 1997) and Clark et al. (Plant Mol. Biol. 
331875-885, 1997). 
Useful P450 sequences may be isolated from any appro 
priate organism. Con?rmation of a sequence’s relatedness to 
a P450 polypeptide disclosed herein may be accomplished by 
a variety of conventional methods, for example, by compar 
ing the sequence With a knoWn p450 sequence found in a 
database. In addition, the activity of any P450 may be evalu 
ated according to any of the techniques described herein. 
P450 Polypeptide Expression 
P450 polypeptides may be produced by transformation of 
a suitable host cell With all or part of a P450 DNA (for 
example, any one of the P450 cDNAs described herein) in a 
suitable expression vehicle or With a plasmid construct engi 
neered for increasing the expression of a P450 polypeptide in 
vivo. 
Those skilled in the ?eld of molecular biology Will appre 
ciate that any of a Wide variety of expression systems may be 
used to provide the recombinant protein. The precise host cell 
used is not critical to the invention. The P450 protein may be 
produced in a prokaryotic host, for example, E. coli TB 1, or in 
a eukaryotic host, for example, Saccharomyces cerevisiae, 
insect cells, mammalian cells (for example, COS 1 or NIH 
3T3 cells), or any of a number of plant cells including, With 
out limitation, algae, tree species, ornamental species, tem 
perate fruit species, tropical fruit species, vegetable species, 
legume species, monocots, dicots, or in any plant of commer 
cial or agricultural signi?cance. Particular examples of suit 
able plant hosts include, but are not limited to, Conifers, 
Petunia, Tomato, Potato, Tobacco, Grape, Arabidopsis, Let 
tuce, Sun?ower, Oilseed rape, Flax, Cotton, Sugarbeet, Cel 
ery, Soybean, Alfalfa, Medicago, Lotus, Vigna, Cucumber, 
Carrot, Eggplant, Cauli?ower, Horseradish, Morning Glory, 
Poplar, Walnut, Apple, Asparagus, Grape, Rice, Maize, Mil 
let, Onion, Barley, Orchard grass, Oat, Rye, Tobacco, and 
Wheat. 
Such cells are available from a Wide range of sources 
including: the American Type Culture Collection (Rockland, 
Md.); or from any of a number seed companies, for example, 
W. Atlee Burpee Seed Co. (Warminster, Pa.), Park Seed Co. 
(Greenwood, SC), Johnny Seed Co. (Albion, Me.), or 
Northrup King Seeds (Harstville, S.C.). Descriptions and 
sources ofuseful host cells are also found in Vasil I. K., Cell 
Culture and Somatic Cell Genetics of Plants, Vol I, II, III 
Laboratory Procedures and Their Applications Academic 
Press, NeW York, 1984; Dixon, R. A., Plant Cell CultureiA 
Practical Approach, IRL Press, Oxford University, 1985; 
Green et al., Plant Tissue and Cell Culture, Academic Press, 
NeW York, 1987; and Gasser and Fraley, Science 24411293, 
(1989). 
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For prokaryotic expression, DNA encoding a P450 
polypeptide is carried on a vector operably linked to control 
signals capable of effecting expression in the prokaryotic 
host. If desired, the coding sequence may contain, at its 5' end, 
a sequence encoding any of the knoWn signal sequences 
capable of effecting secretion of the expressed protein into the 
periplasmic space of the host cell, thereby facilitating recov 
ery of the protein and subsequent puri?cation. Prokaryotes 
most frequently used are various strains of E. coli; hoWever, 
other microbial strains may also be used. Plasmid vectors are 
used Which contain replication origins, selectable markers, 
and control sequences derived from a species compatible With 
the microbial host. Examples of such vectors are found in 
PouWels et al. (supra) or Ausubel et al. (supra). Commonly 
used prokaryotic control sequences (also referred to as “regu 
latory elements”) are de?ned herein to include promoters for 
transcription initiation, optionally With an operator, along 
With ribosome binding site sequences. Promoters commonly 
used to direct protein expression include the beta-lactamase 
(penicillinase), the lactose (lac), the tryptophan (Trp) (Goed 
del et al., Nucl. Acids Res. 814057 (1980)), and the tac pro 
moter systems, as Well as the lambda-derived P.sub.L pro 
moter and N-gene ribosome binding site (Simatake et al., 
Nature 2921128 (1981)). 
One particular bacterial expression system for P450 pro 
duction is the E. coli pET expression system (Novagen). 
According to this expression system, DNA encoding a P450 
is inserted into a pET vector in an orientation designed to 
alloW expression. Since the P450 gene is under the control of 
the T7 regulatory signals, P450 expression is dependent on 
inducing the expression of T7 RNA polymerase in the host 
cell. This is typically achieved using host strains Which 
express T7 RNA polymerase in response to IPTG induction. 
Once produced, recombinant P450 is then isolated according 
to standard methods knoWn in the art, for example, those 
described herein. 
Another bacterial expression system for P450 production 
is the pGEX expression system (Pharmacia). This system 
employs a GST gene fusion system that is designed for high 
level expression of a gene or gene fragment as a fusion protein 
With rapid puri?cation and recovery of the functional gene 
product. The P450 of interest is fused to the carboxyl terminus 
of the glutathione S-transferase protein from Schislosoma 
japonicum and is readily puri?ed from bacterial lysates by 
al?nity chromatography using Glutathione Sepharose 4B. 
Fusion proteins can be recovered under mild conditions by 
elution With glutathione. Cleavage of the glutathione S-trans 
ferase domain from the fusion protein is facilitated by the 
presence of recognition sites for site-speci?c proteases 
upstream of this domain. For example, proteins expressed in 
pGEX-2T plasmids may be cleaved With thrombin; those 
expressed in pGEX-3X may be cleaved With factor Xa. 
Other prokaryotic systems useful for expressing eukary 
otic P450s are described by Cooper (Mutat. Res. 454145-52, 
2000) and Dong et al. (Arch. Biochem. Biophys. 3271254 
259, 1996). In addition, strategies for enhancing the prokary 
otic expression of a cytochrome P450 in combination With 
cytochrome reductase are described in Porter et al. (Drug. 
Metab. Rev. 311159-174, 1999). 
For eukaryotic expression, the method of transformation or 
transfection and the choice of vehicle for expression of the 
P450 Will depend on the ho st system selected. Transformation 
and transfection methods of numerous organisms, for 
example, the baker’s yeast Saccharomyces cerevisiae, are 
described, e.g., in Ausubel et al. (supra); Weissbach and 
Weissbach, Methods for Plant Molecular Biology, Academic 
Press, 1989; Gelvin et al., Plant Molecular Biology Manual, 




























